Picture Berlin Partner HealthCapital RegMed Forum 2018 October 600x60px
Document › Details

Biognosys AG. (3/7/14). "Press Release: Biognosys and FGCZ Announce Collaboration on SpectroDive PRM Testing". Zürich-Schlieren.

Organisations Organisation Biognosys AG
  Organisation 2 ETH Zürich, Functional Genomics Center Zürich (FGCZ)
  Group ETH Zürich (ETHZ)
Products Product SpectroDive™ software (for MRM + PRM testing)
  Product 2 PlasmaDeepDive™ MRM Panel (service or product)
Index term Index term Biognosys–ETH Zürich: mass spectrometry s/w, 201403– collab testing of SpectroDive PRM s/w by FGCZ

Biognosys AG, a Swiss Proteomics Company, and Functional Genomics Center Zurich (FGCZ), a state-of-the-art research and training facility of the University of Zurich and ETH Zurich, announced today the collaboration on a large-scale testing of SpectroDive ™ software for Multiple and Parallel Reaction Monitoring (MRM and PRM, respectively).

MRM is a well-established method for targeted proteomics and is primarily performed on triple quadruple mass spectrometers. PRM was introduced only recently and is performed on the latest generation of high-resolution mass spectrometric instruments. Both methods allow for highly specific and sensitive quantification of proteins from nearly any biological sample.

SpectroDive™ is Biognosys' proprietary software for automated MS method set-up, signal processing and data analysis. It is an integral part of MRM Assay Panels (e.g. PlasmaDeepDive™ 100) that are offered by Biognosys as a plug-and-play solution for multiplexed protein quantification.

Compared to classical MRM, PRM relies on high mass precision data that allows the removal of interfering signals providing additional advantages for peptide detection and quantification. Before the official release, Biognosys and FGCZ initiated a collaboration in order to test the software on a broader range of different experiments and further develop the PRM method. The FGCZ was chosen due to its scientific excellence, diversity of instrument set-ups and experience with large-scale experiments.

Biognosys currently offers its MRM and PRM capabilities as a service and standardized off-the-shelf MRM Assay Panels, while the PRM Assay Panels are planned to be made commercially available in the near future.

About Biognosys

Biognosys is the leading proteomics company offering services and products for highly multiplexed protein quantification. Founded in 2008 as spin-off from the lab of proteomics pioneer Ruedi Aebersold at ETH Zurich, Biognosys is dedicated to transform life science with superior technology and software.

About FGCZ

The Functional Genomics Center Zurich (FGCZ) is a joint state-of-the-art research and training facility of the ETH Zurich and the University of Zurich. With latest technologies and expert support for Omics research, the FGCZ carries out research projects and technology development in collaboration with the Zurich Life Science research community.


Record changed: 2016-01-10


Picture Berlin Partner HealthCapital RegMed Forum 2018 October iito 600x60px

More documents for Biognosys AG

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture Berlin Partner HealthCapital RegMed Forum 2018 October 600x60px

» top